When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PGNX - Mid-stage study underway for Progenics' I-131 1095 in prostate cancer
Progenics Pharmaceuticals Inc.
The first patient has been dosed in a Phase 2 clinical trial, ARROW, evaluating Progenics Pharmaceuticals' (NASDAQ:PGNX) I-131 1095 radiotherapy, combined with Pfizer (NYSE:PFE) and Astellas' (OTCPK:ALPMY) XTANDI (enzalutamide), for the treatment of metastatic castration-resistant prostate cancer.
More news on: Progenics Pharmaceuticals, Inc., Pfizer Inc., Astellas Pharma Inc., Healthcare stocks news,